Conversion therapy and maintenance therapy for primary hepatocellular carcinoma-Reference-Cited by-同舟云学术

Conversion therapy and maintenance therapy for primary hepatocellular carcinoma

Published:2021-06-30 Issue:3 Volume:15 Page:155-160
ISSN:1881-7815
Container-title:BioScience Trends
language:en
Short-container-title:BST

Author:

Zhou Hongyuan¹,Song Tianqiang¹

Affiliation:

1. Department of Hepatobiliary, HCC Research Center for Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine,Health(social science)

Link

https://www.jstage.jst.go.jp/article/bst/15/3/15_2021.01091/_pdf

Reference28 articles.

1. 1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115-132.

2. 2. Sperber A, Bangdiwala S, Drossman D, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, Results of Rome Foundation global study. Gastroenterology. 2021; 160:99-114.e113.

3. 3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132:2557-2576.

4. 4. Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl. 2015; 21:1142-1152.

5. 5. Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg. 1993; 217:149-154.

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obovatol inhibits proliferation, invasion and immune escape of hepatocellular carcinoma cells through modulating the JAK/STST3/PD-L1 pathway;International Immunopharmacology;2024-11

2. Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials;Biomedicine & Pharmacotherapy;2024-10

3. 3D bioprinting of an in vitro hepatoma microenvironment model: Establishment, evaluation, and anticancer drug testing;Acta Biomaterialia;2024-09

4. Development and optimization of a self micro-emulsifying drug delivery system (SMEDDS) for co-administration of sorafenib and curcumin;Drug Delivery and Translational Research;2024-08-29

5. Periplocin improves the sensitivity of oxaliplatin-resistant hepatocellular carcinoma cells by inhibiting M2 macrophage polarization;Biomolecules and Biomedicine;2024-08-27